Health and science news from Florida. Personal account, views my own.
Boynton Beach, FL
Joined April 2009
- Tweets14.2K
- Following5.3K
- Followers3.6K
- Likes7.7K
Stacey S DeLoye retweeted
1) 🔬 New funding opportunity for ME/CFS research! Solve is now accepting submissions for their Ramsay Research Grant Program!
Funding is between $50.000 - $150.000 depending on the category.
The deadline to apply is Friday, November 13, 2026.
Stacey S DeLoye retweeted
The US government will give your startup up to $1.55M and take 0% equity.
@NSF's America's Seed Fund is open again after Congress reauthorized it in April.
Three tracks:
- Phase I: up to $305K to prove the idea
- Phase II: up to $1.25M to build it
- Fast-Track: up to $1.55M, both phases in one go
Who can apply:
- US-based startups with 500 or fewer employees
- 51%+ owned by US citizens or permanent residents
- Not majority owned by VCs
- All the work done in the US
How it works:
- Send a 3-page Project Pitch first
- NSF invites the best ones to submit a full proposal
- Next full proposal deadline: Nov 4
Phase I funding rates have run about 10 to 20%. It's work, but nobody takes your cap table.
Application link 👉 seedfund.nsf.gov
Bookmark and tag a tech founder who needs this.
Stacey S DeLoye retweeted
New from France 🇫🇷
Interesting long Covid research where all participants satisfy ME/CFS criteria
Evidence for transcriptomic changes impacting muscle contraction in patients with post-acute COVID-19 syndrome
sciencedirect.com/science/ar…
#LongCovid #MEcfs
ALT Post-acute COVID-19 syndrome (PACS) overlaps with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) but, due to frequent muscle pain and exertional intolerance, neuromuscular disorders are often suspected. We report the results of a comprehensive neuromuscular evaluation in 27 PACS patients (22F/5M; median age 41 ys). All patients developed chronic fatigue (>6 months), post-exertional malaise, and cognitive impairment, with muscle pain in 88% but no neuromuscular deficits at clinical examination. 18/27 patients were unable to work. All patients fulfilled established ME/CFS diagnostic criteria (CDC 1994, ICC 2011, Inst Medicine 2015, NICE 2021). Electrophysiological studies and CK levels were normal. Brain 18FDG-PET/MRI (14/27) showed posterior hypometabolism in 8/14. Muscle biopsy (7/27) showed moderate dysimmune changes in 2/7. Exploratory transcriptomic analyses performed in muscle biopsies from PACS patients and pre-COVID controls unveiled in PACS differentially expressed
Stacey S DeLoye retweeted
Sharing for those here in the Bay: @ChronicleBioAI is looking for ME/CFS patients to enroll in their biobank study who are able to give a blood sample at their Menlo Park lab. They are currently looking at specific biomarkers and immune cells.
connect.chroniclebio.com/sig… – at Menlo Park, CA
Stacey S DeLoye retweeted
ARDS, acute respiratory distress syndrome, strikes 2M worldwide, with 40% mortality. A new therapy shows promise. wertheim.scripps.ufl.edu/202…
@WertheimUFScrip #ARDS #ARDSAwareness #clinicaltrials @UFHealth @UF_Research
ALT Joe G.N. Garcia, M.D. and Susannah Patarroyo-White, senior staff scientist, work in the laboratory at The Wertheim UF Scripps Institute to develop a treatment for a life-threatening lung condition called acute respiratory distress syndrome (ARDS).
Stacey S DeLoye retweeted
The most promising longevity drug isn't a peptide or metformin. It's the Shingles vaccine.
New data shows it slows biological aging and lowers systemic inflammation for 4+ years post-shot. We are seeing a 20% reduction in new dementia diagnoses and a 25% lower risk of stroke.
Stop waiting for a magic pill. One is already on the shelf. – at New York, USA
🤖 Made with AI
Stacey S DeLoye retweeted
Long term follow up of a phase 1
trial of an mRNA tumor vaccine shows that 7/8 patients with pancreatic cancer, who mounted an immune response to the vaccine, are still alive 6 years later. This is breathtaking data and shows the promise of mRNA vaccines. nbcnews.com/health/cancer/pa…
Stacey S DeLoye retweeted
The independent research by a world renowned breast cancer oncologist at UCLA, Dr Aditya Barda, breaks news today at AACR that consistently shows regardless of the stage of BREAST CANCER, that post Covid lymphopenia results in poorer prognosis, poorer response to treatment and even 2x higher recurrence when patients are in remission. The relationship of low NK and low T cells to breast cancer ( and frankly all cancers ) is so clear.
Will share his data that he presented at major breast cancer conferences and now at AACR next. Very compelling
Stacey S DeLoye retweeted
Study of neuro #LongCovid patients found pTau-181 (marker of Alzheimer's/brain injury) increased by 59% after COVID.
Interestingly, levels increased more AFTER 1.5 years from infection (only 15% increased in the before-1.5 year time period).
thelancet.com/journals/ebiom… 1/
Stacey S DeLoye retweeted
University of Florida recognized as one of Forbes' 'New Ivies' for 2026 | Click on the image to read the full story wpbf.com/article/uf-universi…
Stacey S DeLoye retweeted
“An analysis by the Florida Policy Institute found that Florida would have to double its sales tax to 12% to replace lost property tax revenue. The move would make the state sales tax the nation's highest.”
yahoo.com/news/articles/desa…
Stacey S DeLoye retweeted
Here is our updated database of grants for early careers researchers in all fields.
It goes way beyond traditional NIH and NSF funding opportunities. We list 428 types of grants.
Download it here: research.jhu.edu/rdt/funding…
Stacey S DeLoye retweeted
A recent study in Nature Communications reveals over 250 metabolic enzymes located directly on chromatin, a discovery that vastly expands the previously known count of only about 20.
nature.com/articles/s41467-0…
Stacey S DeLoye retweeted
New research suggests antibodies from people with ME/CFS and Long COVID may directly change how cells handle energy and inflammation.
The study found these antibodies may fragment mitochondria and alter immune signals.
Stacey S DeLoye retweeted
Prevalence and Symptoms of Post-COVID-19 Syndrome in Active-Duty Military Personnel
🚨The ALARMING USA army news today:
Over 42% of active-duty military personnel who contracted COVID-19 developed long-lasting post-COVID syndrome—dominated by pulmonary, neurological, and fatigue issues—threatening their fitness, readiness, and the military’s ability to respond to threats.
➡️A large retrospective study analysed electronic health records from the U.S. Military Health System (2019–2024), identifying post-COVID-19 syndrome in 42.8% of 650,173 COVID-19 cases among active-duty personnel. The cohort was predominantly male (74.1%), young (mean age 31.3 years), and enlisted (83.3%).
➡️Findings:
1. Prevalence:
- Post-COVID-19 syndrome identified in 42.8% of 650,173 COVID-19 cases,
- “In our sample of 650,173 COVID cases among active-duty military personnel, a total of 278,278 were identified as having post-COVID-19 syndrome (42.8%).”
2. Demographics:
- Predominantly male (74.1%),
- Young population (mean age 31.3 years),
- Mostly enlisted ranks (83.3%),
3. Most common persistent symptoms:
- Pulmonary issues: 22.4% (median duration 670 days),
- Neurological problems: 14.6% (median 576 days),
- Fatigue: 13.5% (median 667 days),
- Digestive issues: 12.5%,
- Fever: 11.5%,
- Cognitive symptoms: only 3.7% but longest persistence (median 710 days),
4. Sex differences:
- Females → higher odds of neurological (OR 1.645) and digestive symptoms,
- Females → lower odds of pulmonary (OR 0.851) and cognitive symptoms,
5. Comorbidity impact:
- Obesity → triples odds of pulmonary symptoms,
- Anxiety → quadruples odds of cognitive symptoms,
- Other comorbidities significantly amplify risk across domains,
6. Military-specific patterns:
- Rank differences: warrant officers showed higher fatigue and pulmonary odds,
- Service branch differences: Air Force personnel had elevated pulmonary symptoms (possible environmental exposure link),
7. Comparison to civilians:
- Military pattern differs: pulmonary and neurological issues more prominent than the fatigue-dominant profile typical in civilian populations,
➡️‼️So, post-COVID-19 syndrome affects over 40% of young, fit active-duty service members post-C19, and poses a serious long-term threat to military medical readiness and operational capability. #REINFECTIONS
➡️‼️And AGAIN: Long COVID strikes millions worldwide, often with persistent pulmonary, neurological, and fatigue symptoms lasting months to years, severely impairing daily function, work productivity, and overall quality of life in a substantial portion of those infected. #LONGCOVIDAWARENESSMONTH
#AVOIDREINFECTIONS #AVOIDSARS2
amjmedsci.org/article/S0002-…
Stacey S DeLoye retweeted
🐢The Palm Beaches is officially the Sea Turtle Capital of Florida, with more loggerhead nests per mile than anywhere in the U.S.
March–Oct, nearly 2M hatchlings begin their journey here. Visit @loggerheadmarinelifecenter, USA Today’s No. 1 Free Attraction (2024–2025). 💚
Stacey S DeLoye retweeted
Simmaron publication shows mechanisms of #PEM in #ME! Our new findings show a lack of ATG13 inside cells induces macrophages to take on an inflammatory role, impairing myelin in muscles, in processes aggravated by exercise. #Longcovid @UWM @SpringerNature link.springer.com/article/10…
Stacey S DeLoye retweeted
thelancet.com/journals/lanep… risk of post covid condition no longer detectable in new infections
Stacey S DeLoye retweeted
From @actionforme on the blue site:
“Today we’re delighted to launch Sequence ME & Long Covid - the world’s largest long-read, whole-genome study of any disease 🔬
🧬 This £20 million ground breaking initiative will explore the root causes of ME and Long Covid, …”
#MEcfs
1/
ALT Image of a DNA double helix against a soft blue background with light particles. The Action for ME logo appears in the top right corner. Text on the image reads: “Research News – SequenceME and Long Covid study launches. The world’s largest long-read, whole-genome study of any disease.”
Stacey S DeLoye retweeted
Applications are open for Broad’s 2026 Media Boot Camp!
Science/health reporters and editors: Join us in Cambridge (April 30–May 1) for a deep dive into emerging stories in biomedicine.
Hotel & meals provided. Applications due March 20. Learn more here: broad.io/mediabootcamp
